If AstraZeneca’s ditching of its plans last January for a long-expected £450 million investment in a vaccine manufacturing in Liverpool was a bright red warning sign, then Merck’s decision this week to can a half-built £1bn research centre in London is a car crash. Pharma executives have been warning the UK’s government ever since it […]
ViCentra raises $85M to scale manufacturing and accelerate market penetration of Kaleido insulin patch pump ViCentra announces the successful close of an upsized $85 million Series D financing led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from […]
September is World Alzheimer’s Month, and while advances in treatment of the degenerative brain disease have been big news over the last couple of years, it is worth reflecting on the wider picture. Alzheimer’s – together with other forms of dementia – become much more frequent as people age. The growing incidence of dementia worldwide […]
The winds they are a-changin’, with the tail-end of Hurricane Erin bringing what feels like an abrupt end to summer here in northern Europe. And what will the new season bring to the world of biotech and pharma? Only time will tell. Optimum’s clients are certainly gearing up though – and we can all expect […]
The US administration’s decision to stop federal funding worth $500 million for research into mRNA-based vaccines has not gone down well with the scientific community. Researchers argue the premise for the cuts – that in the words of US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., mRNA vaccines “fail to […]
